Board Properly Declared Copaxone Patents Invalid, Federal Circuit Finds

Mealey's (October 15, 2018, 1:25 PM EDT) -- WASHINGTON, D.C. — On the same day it affirmed a Delaware federal judge’s determination of invalidity with regard to four patents covering the multiple sclerosis drug Copaxone, the Federal Circuit U.S....
To view the full article, register now.